Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain FDA Decision: Disc Medicine (IRON)

The Phase 3 date for Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain by Disc Medicine (IRON) is scheduled for October 1, 2026. This is the target date for the FDA to make a decision on this application.

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain is being developed by Disc Medicine for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain receives FDA approval, Disc Medicine (IRON) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IRON on DilutionWatch at dilutionwatch.com/stock/IRON.html.

You can view the full BiotechSigns company profile for Disc Medicine (IRON) at biotechsign.com/app/company/IRON, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.